The purpose of this investigation was to compare the dental health related behaviour of groups of 13-14-year-old English and Scottish schoolchildren, in order to explain the differences in caries experience demonstrated by the 1983 national children's dental health survey. The data-bank of health-reported behaviour of schoolchildren in the United Kingdom held by the Schools Health Education Unit (SHEU), Exeter University was used. Seventy-four secondary schools in England and 8 secondary schools in Scotland participated in the study. The information obtained from the questionnaires of 2283 children in England and 259 children in Scotland was examined. The daily intake of sweets, sugary fizzy drinks and a 'sugary' carbohydrate index were analysed from a 24-hour recall dietary record. There was a general consistency between the findings from the SHEU data and the 1983 United Kingdom children dental health survey (Todd & Dodd 1985) with regard to toothbrushing behaviour and dental attendance. Therefore, as dietary information was not gathered in the 1983 survey, exploration of the SHEU data bank allowed a comparison of the dietary habits between Scottish and English schoolchildren. Scottish schoolchildren consumed more sugar-containing items than English schoolchildren. Children from lower social groups in both countries consumed more sugar; however, the major dietary difference between the two countries was not in the mean number of sweets consumed or the daily sugary carbohydrate index, but in the mean number of sugary fizzy drinks consumed.
Download full-text PDF |
Source |
---|
JMIR Med Educ
January 2025
Digital Society Initiative, University of Zurich, Zurich, Switzerland.
Background: The increased use of digital data in health research demands interdisciplinary collaborations to address its methodological complexities and challenges. This often entails merging the linear deductive approach of health research with the explorative iterative approach of data science. However, there is a lack of structured teaching courses and guidance on how to effectively and constructively bridge different disciplines and research approaches.
View Article and Find Full Text PDFPurpose: The Hematology Oncology Pharmacist Association Oral Chemotherapy Collaborative (HOPA OCC) developed practice-based tools to use in program development and improvement for the management of patients receiving oral anticancer agents (OAAs).
Methods: These tools include a baseline OAA program assessment, clinical OAA adherence tool, and OAA dashboard. HOPA OCC distributed these tools to teams participating in the 6-month HOPA ASCO Quality Training Programs (QTPs).
Ann Am Thorac Soc
January 2025
The University of Tokyo, Department of Clinical Epidemiology and Health Economics, Bunkyo-ku, Tokyo, Japan.
Rationale: Although the guidelines generally omit routine antibiotic prophylaxis for diagnostic bronchoscopy, this recommendation is primarily based on studies with relatively small sample sizes conducted at single institutions. Moreover, the applicability of recent technical and procedural advancements to these guidelines remains uncertain.
Objectives: To evaluate whether oral prophylactic antibiotic administration for diagnostic bronchoscopy reduces post-bronchoscopy infections among non-infectious diseases in the current setting.
PLoS One
January 2025
Cancer Center, Kagoshima University Hospital, Kagoshima, Japan.
Kinase-related gene fusion and point mutations play pivotal roles as drivers in cancer, necessitating optimized, targeted therapy against these alterations. The efficacy of molecularly targeted therapeutics varies depending on the specific alteration, with great success reported for such therapeutics in the treatment of cancer with kinase fusion proteins. However, the involvement of actionable alterations in solid tumors, especially regarding kinase fusions, remains unclear.
View Article and Find Full Text PDFBr J Dermatol
January 2025
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety profiles, particularly oral medications. Orismilast is a novel first-in-class oral phosphodiesterase-4 (PDE4) B/D inhibitor under investigation for the treatment of moderate-to-severe AD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!